2025 Q4 -tulosraportti
Vain PDF
67 päivää sitten
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 26 168 | - | - | ||
| 300 | - | - | ||
| 3 521 | - | - | ||
| 506 | - | - | ||
| 636 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
·1 t sittenIf the Big Pharma PoC data delivers and Circio enters a significant licensing agreement with upfront payment and milestones, it could open up more strategic opportunities than just financing further development. Erik has previously mentioned that capital well over 300 MNOK could allow for investments or acquisitions of complementary technology. Then the question becomes: What is most value-creating? CircVec already appears to be a strong platform with higher gene expression, longer expression duration, and potential for dose reduction. But in gene therapy, delivery is at least as important as the RNA platform itself. The interesting thing is that Circio is already building in this direction through collaborations with, among others, Acuitas (LNP), Certest, and GenAssist, while the company continues to develop the circVec platform. This may indicate that the strategy is to combine leading circRNA technology with strong delivery solutions rather than standing alone. If strong PoC data eventually leads to a larger licensing agreement and solid cash reserves, the next natural step could be to further strengthen the delivery side – either through new partnerships, investments, or acquisitions of complementary technology such as LNP, AAV-capsids, or other targeted delivery. In that case, it could make Circio an even more complete platform within RNA and gene therapy. What do you think – is this a logical next step if the commercial pieces fall into place?
·3 t sittenNow Circio is a financed platform company with several parallel development tracks, increasing external interest, and a technology that will now be tested further at a much higher pace.
·6 t sittenI understand that the shares bought through the warrant program were to be made available on June 19th. Are they transferred to the Nordnet account automatically or does one have to do something oneself?
·21 t sittenPlease continue, so we can have some fun now that it's the weekend
·20 t sittenImagine that an incredibly smart analyst predicted a price of 5.8 in Circio within a couple of days, but it was a typo 8.5! Furthermore, Middelfart is a lovely town. Can recommend cafe Razz
·1 päivä sittenNice with weekend 🍺⚽️ But it's not often I look forward to Monday. 😅
·28 min sittenStrong to close at 8.35kr on Friday! Interest was significantly greater for buying than selling in closing trade. This despite Svergie etc. being closed. Next Monday! Something tells me the seller side is even a bit more tight-fisted and the buyer side even a bit more hungry when the next days are about San Diego 🇺🇸 and a partnering conference. With a money bin 10 meters deep at its deepest, it will be interesting💰
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
67 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·1 t sittenIf the Big Pharma PoC data delivers and Circio enters a significant licensing agreement with upfront payment and milestones, it could open up more strategic opportunities than just financing further development. Erik has previously mentioned that capital well over 300 MNOK could allow for investments or acquisitions of complementary technology. Then the question becomes: What is most value-creating? CircVec already appears to be a strong platform with higher gene expression, longer expression duration, and potential for dose reduction. But in gene therapy, delivery is at least as important as the RNA platform itself. The interesting thing is that Circio is already building in this direction through collaborations with, among others, Acuitas (LNP), Certest, and GenAssist, while the company continues to develop the circVec platform. This may indicate that the strategy is to combine leading circRNA technology with strong delivery solutions rather than standing alone. If strong PoC data eventually leads to a larger licensing agreement and solid cash reserves, the next natural step could be to further strengthen the delivery side – either through new partnerships, investments, or acquisitions of complementary technology such as LNP, AAV-capsids, or other targeted delivery. In that case, it could make Circio an even more complete platform within RNA and gene therapy. What do you think – is this a logical next step if the commercial pieces fall into place?
- ·3 t sittenNow Circio is a financed platform company with several parallel development tracks, increasing external interest, and a technology that will now be tested further at a much higher pace.
- ·6 t sittenI understand that the shares bought through the warrant program were to be made available on June 19th. Are they transferred to the Nordnet account automatically or does one have to do something oneself?
- ·21 t sittenPlease continue, so we can have some fun now that it's the weekend·20 t sittenImagine that an incredibly smart analyst predicted a price of 5.8 in Circio within a couple of days, but it was a typo 8.5! Furthermore, Middelfart is a lovely town. Can recommend cafe Razz
- ·1 päivä sittenNice with weekend 🍺⚽️ But it's not often I look forward to Monday. 😅·28 min sittenStrong to close at 8.35kr on Friday! Interest was significantly greater for buying than selling in closing trade. This despite Svergie etc. being closed. Next Monday! Something tells me the seller side is even a bit more tight-fisted and the buyer side even a bit more hungry when the next days are about San Diego 🇺🇸 and a partnering conference. With a money bin 10 meters deep at its deepest, it will be interesting💰
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 26 168 | - | - | ||
| 300 | - | - | ||
| 3 521 | - | - | ||
| 506 | - | - | ||
| 636 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
2025 Q4 -tulosraportti
Vain PDF
67 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·1 t sittenIf the Big Pharma PoC data delivers and Circio enters a significant licensing agreement with upfront payment and milestones, it could open up more strategic opportunities than just financing further development. Erik has previously mentioned that capital well over 300 MNOK could allow for investments or acquisitions of complementary technology. Then the question becomes: What is most value-creating? CircVec already appears to be a strong platform with higher gene expression, longer expression duration, and potential for dose reduction. But in gene therapy, delivery is at least as important as the RNA platform itself. The interesting thing is that Circio is already building in this direction through collaborations with, among others, Acuitas (LNP), Certest, and GenAssist, while the company continues to develop the circVec platform. This may indicate that the strategy is to combine leading circRNA technology with strong delivery solutions rather than standing alone. If strong PoC data eventually leads to a larger licensing agreement and solid cash reserves, the next natural step could be to further strengthen the delivery side – either through new partnerships, investments, or acquisitions of complementary technology such as LNP, AAV-capsids, or other targeted delivery. In that case, it could make Circio an even more complete platform within RNA and gene therapy. What do you think – is this a logical next step if the commercial pieces fall into place?
- ·3 t sittenNow Circio is a financed platform company with several parallel development tracks, increasing external interest, and a technology that will now be tested further at a much higher pace.
- ·6 t sittenI understand that the shares bought through the warrant program were to be made available on June 19th. Are they transferred to the Nordnet account automatically or does one have to do something oneself?
- ·21 t sittenPlease continue, so we can have some fun now that it's the weekend·20 t sittenImagine that an incredibly smart analyst predicted a price of 5.8 in Circio within a couple of days, but it was a typo 8.5! Furthermore, Middelfart is a lovely town. Can recommend cafe Razz
- ·1 päivä sittenNice with weekend 🍺⚽️ But it's not often I look forward to Monday. 😅·28 min sittenStrong to close at 8.35kr on Friday! Interest was significantly greater for buying than selling in closing trade. This despite Svergie etc. being closed. Next Monday! Something tells me the seller side is even a bit more tight-fisted and the buyer side even a bit more hungry when the next days are about San Diego 🇺🇸 and a partnering conference. With a money bin 10 meters deep at its deepest, it will be interesting💰
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 26 168 | - | - | ||
| 300 | - | - | ||
| 3 521 | - | - | ||
| 506 | - | - | ||
| 636 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt